The tariff threat come just a few days after the White House sent letters to major drugmakers demanding slashed prices for US ...

Contract Development and Manufacturing Organizations (CDMOs) have carved out a lucrative niche within the biopharma industry, ...

CEO says pharma executives discussed Trump's call to launch DTC initiatives under his Most Favored Nation policy to lower U.S ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc., in collaboration with Astellas Pharma Global Development, ...

Pharmaceutical major recorded a revenue jump to $14.65 billion, exceeding the market expectations. The company also raised ...

Pfizer's Albert Bourla told investors that major drugmakers are "ready to roll up their sleeves" and build out more direct-to ...

Pfizer CEO says drugmakers ‘are all ready to roll up their sleeves and execute’ as president demands more direct-to-consumer ...

Pfizer stock rises after a strong Q2, boosted by cost savings, pipeline progress, and an upgraded 2025 profit outlook.

The drug maker reports second-quarter earnings Tuesday, and investors continue to eye a list of glaring problems.

Pfizer's beleaguered obesity strategy has hit another setback as the pharma jettisoned its third and final GLP-1 agonist, ...

Home Biotech Stocks Biotech Stocks Pfizer stokes pharma, biotechs slip By Val Brickates Kennedy , MarketWatch Published: Feb. 8, 2006 at 5:04 p.m. ET Share ...